ClinicalTrials.gg

TargetBeta

TNFRSF9

TNF receptor superfamily member 9 · also CD137, 4-1BB, ILA · CD molecules

14 programs in company-led studies act on TNFRSF9, from 12 companies: 3 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024ruleNanjing Leads Biolabsphase 31010 runningCD274NCIt
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 333 runningGPC3NCIt
acasunlimabruleGenmabphase 361 runningCD274NCIt
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleABL Biophase 222 runningVTCN1NCIt
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 222 runningCEACAM5the company's pipeline
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314ruleBioNTechphase 222 runningEPCAMNCIt
CD137/Nectin-4 Bispecific-targeting Agent BT7480ruleBicycleTxphase 222 running–NCIt
Anti-CD137 Agonistic Monoclonal Antibody CTX-471ruleCompass Therapeuticsphase 221 running–NCIt
Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505ruleRegeneron Pharmaceuticalsphase 211 runningFOLH1NCIt
LM-2417Sino Biopharmaceuticalphase 211 runningSLC34A2the company's pipeline
clesitamigHoffmann-La Rochephase 121 runningCD3E, DLL3a judged reading
Allogeneic iPSC-derived CD58KO Anti-MICA/MICB CAR-ADR-expressing T-cells FT836ruleFate Therapeuticsphase 111 runningCD58, FDXR, MICA, MICBNCIt
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceuticalphase 111 runningCD274the company's pipeline
Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015ruleMedigenephase 111 runningCTAG2, PDCD1NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.